Abemaciclib vs Ribociclib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline

Abemaciclib · Verzenio

Marketed by Eli Lilly

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT02107703 · Phase 3 · active, not recruiting

This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.

Next expected readout: December 2026 · NCT05305924 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)

Result source: NCT02107703

Ribociclib

Marketed by Novartis

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT02422615 · Phase 3 · completed

The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.

Next expected readout: November 2026 · NCT02608216 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)

Result source: NCT02422615

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAbemaciclibRibociclib
PFS, median16.4 vs 9.3+7.1 vs placebon 446NCT02107703
11 other results
20.5 vs 12.8+7.7 vs placebon 484NCT02422615
9 other results
OS, median45.8 vs 37.3+8.5 vs placebon 446NCT02107703
6 other results
63.9 vs 51.4+12.5 vs placebon 334NCT01958021
1 other result
ORR35.2% vs 16.1%+19.1 vs placebon 446NCT02107703
4 other results
  • 26.3% vs 10% n 38 · Phase 1/2 · primary NCT03280563
  • 19.7% n 132 · Phase 2 · primary NCT02102490
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
32.4% vs 21.5%+10.9 vs placebon 484NCT02422615
6 other results
  • 40.9% vs 29.7% n 335 · Phase 3 · secondary NCT02278120
  • 40.7% vs 27.5% n 334 · Phase 3 · secondary NCT01958021
  • 29.3% n 3246 · Phase 3 · secondary NCT02941926
  • 45.3% 600 mg · n 188 · Phase 2 · primary NCT03822468
  • 41.5% 400 mg · n 188 · Phase 2 · primary NCT03822468
  • 66.1% vs 61.8% 600 mg · n 112 · Phase 2 · secondary NCT03839823
Clinical benefit rate72.2% vs 56.1%+16.1 vs placebon 446NCT02107703
8 other results
70.2% vs 62.8%+7.4 vs placebon 484NCT02422615
4 other results
  • 79.1% vs 69.7% n 335 · Phase 3 · secondary NCT02278120
  • 79.6% vs 72.8% n 334 · Phase 3 · secondary NCT01958021
  • 70.7% n 3246 · Phase 3 · secondary NCT02941926
  • 81.3% vs 74.5% 600 mg · n 112 · Phase 2 · secondary NCT03839823

PFS, median

Abemaciclib
16.4 vs 9.3+7.1 vs placebon 446NCT02107703
11 other results
Ribociclib
20.5 vs 12.8+7.7 vs placebon 484NCT02422615
9 other results

OS, median

Abemaciclib
45.8 vs 37.3+8.5 vs placebon 446NCT02107703
6 other results
Ribociclib
63.9 vs 51.4+12.5 vs placebon 334NCT01958021
1 other result

ORR

Abemaciclib
35.2% vs 16.1%+19.1 vs placebon 446NCT02107703
4 other results
  • 26.3% vs 10% n 38 · Phase 1/2 · primary NCT03280563
  • 19.7% n 132 · Phase 2 · primary NCT02102490
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
Ribociclib
32.4% vs 21.5%+10.9 vs placebon 484NCT02422615
6 other results
  • 40.9% vs 29.7% n 335 · Phase 3 · secondary NCT02278120
  • 40.7% vs 27.5% n 334 · Phase 3 · secondary NCT01958021
  • 29.3% n 3246 · Phase 3 · secondary NCT02941926
  • 45.3% 600 mg · n 188 · Phase 2 · primary NCT03822468
  • 41.5% 400 mg · n 188 · Phase 2 · primary NCT03822468
  • 66.1% vs 61.8% 600 mg · n 112 · Phase 2 · secondary NCT03839823

Clinical benefit rate

Abemaciclib
72.2% vs 56.1%+16.1 vs placebon 446NCT02107703
8 other results
Ribociclib
70.2% vs 62.8%+7.4 vs placebon 484NCT02422615
4 other results
  • 79.1% vs 69.7% n 335 · Phase 3 · secondary NCT02278120
  • 79.6% vs 72.8% n 334 · Phase 3 · secondary NCT01958021
  • 70.7% n 3246 · Phase 3 · secondary NCT02941926
  • 81.3% vs 74.5% 600 mg · n 112 · Phase 2 · secondary NCT03839823
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. Abemaciclib: 12 of 12 rows · Ribociclib: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAbemaciclib
Rows use multiple source trials
Ribociclib
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
42.4% (n=132)a,b,c,d
NCT02102490 · Phase 2
4 other source trials
13% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.9% (n=52)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
9.1% (n=22)
NCT02308020 · Phase 2 · registry result, not featured evidence
70.7% (n=3246)a,b,c,d
NCT02941926 · Phase 3 · combination
Duration of Response
time to event · months
NA vs 25.6 placebo monthsb,d
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.36 vs 13.03 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
NA vs NA placebo monthsb,d
NCT02422615 · Phase 3 · combination
3 other source trials
21.3 vs 17.5 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
45.2 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
37 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Duration of Response
time to event · months
No placebo or comparator arm
8.6 monthse,c,d
NCT02102490 · Phase 2
4 other source trials
11.12 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
17.54 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
5.78 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
4.63 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
28.8 months600 mgf,e,c,d
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
26.5 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
ORR
responder rate · % of participants
No placebo or comparator arm
19.7% (n=132)a,b,c,d
NCT02102490 · Phase 2
29.3% (n=3246)a,b,c,d
NCT02941926 · Phase 3 · combination
2 other source trials
41.5% (n=188)400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
45.3% (n=188)600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
ORR
event count · % of participants
No placebo or comparator arm
60.6% (n=33)*1000 mgf,g,h,d
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
show 3 more doses
19.4% (n=31)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
3.8% (n=26)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.7% (n=15)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
50% (n=2)*g,h,d
NCT03477396 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
Overall Survival
time to event · months
No placebo or comparator arm
22.32 monthsa,e,c,d
NCT02102490 · Phase 2
4 other source trials
10.06 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
13.38 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
7.13 months
NCT02308020 · Phase 2 · registry result, not featured evidence
2.93 months
NCT02308020 · Phase 2 · registry result, not featured evidence
NA monthsf,a,e,c,d
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
6 monthsa,e,c,d
NCT02102490 · Phase 2
8 other source trials
2.07 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
4.41 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
1.45 months
NCT02308020 · Phase 2 · registry result, not featured evidence
1.22 months
NCT02308020 · Phase 2 · registry result, not featured evidence
13.6 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
2.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
NA months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
21.8 monthsf,a,e,c,d
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
16.5 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
8.8 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
Time to Response
time to event · months
No placebo or comparator arm
3.52 months1000 mgf,g,h,c,d
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
show 3 more doses
5.45 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1.94 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
9.36 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
9 months600 mgf,g,h,c,d
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
13.1 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
Dropout rate
25.6%i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
5.3%
NCT02102490 · Phase 2
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
16.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
8.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
25%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
34.5%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
17.5%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestoneRibociclib + Fulvestrantj
NCT02422615 · Phase 3 · combination
show 27 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestoneRibociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
59.9%
NCT02941926 · Phase 3 · combination
68.7%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
76.9%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
87.9%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePostmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePremenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
68.8%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
3.2%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
—
NCT02102490 · Phase 2
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
18.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
12.9%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
25%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
19.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
20%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
10.5%Ribociclib + Fulvestrantj
NCT02422615 · Phase 3 · combination
show 27 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
4.8%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
11.4%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
15.5%
NCT02941926 · Phase 3 · combination
22.6%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
23.1%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
17.8%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
11.8%PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
6.5%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
1.3%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
12.8%600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
11.2%400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
7.1%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
29.3%i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
25%
NCT02102490 · Phase 2
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
33.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
21.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
22.2%Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
27.6%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
28.6%Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
41.2%Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
35.9%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
51.6%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
37.5%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
50%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
26.7%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
—Ribociclib + Fulvestrantj
NCT02422615 · Phase 3 · combination
show 27 more results
37.1%Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
24.2%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
25%Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
32.3%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT02941926 · Phase 3 · combination
30.4%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
27.3%Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
19.2%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
28.7%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
29.4%PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
0%PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
27.3%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
17.7%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
19.7%600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
20.2%400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
15.2%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
6.7%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
i
diarrhoea 87.1% (placebo 27.8%)
neutropenia 49.7% (placebo 3.6%)
nausea 49.4% (placebo 24.7%)
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 23 more results
diarrhoea 90.9%
nausea 67.4%
fatigue 47.7%
NCT02102490 · Phase 2
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
200 mg
diarrhoea 87.5%
nausea 62.5%
anaemia 58.3%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 91.7%
nausea 58.3%
anaemia 41.7%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 95.7%
anaemia 47.8%
nausea 47.8%
NCT03703466 · Phase 2 · registry result, not featured evidence
diarrhoea 55.6%
fatigue 33.3%
nausea 33.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 77.6%
fatigue 48.3%
nausea 44.8%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
alanine aminotransferase increased 66.7%
anaemia 44.4%
diarrhoea 44.4%
NCT02308020 · Phase 2 · registry result, not featured evidence
diarrhoea 53.6%
fatigue 39.3%
nausea 28.6%
NCT02308020 · Phase 2 · registry result, not featured evidence
abdominal pain 21.7%
diarrhoea 21.7%
neutropenia 21.7%
NCT02308020 · Phase 2 · registry result, not featured evidence
fatigue 52.9%
nausea 41.2%
diarrhoea 35.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 84.6%
fatigue 43.6%
nausea 43.6%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
decreased appetite 66.7%
vomiting 66.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
anaemia 100%
diarrhoea 100%
aspartate aminotransferase increased 85.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 85.7%
asthenia 71.4%
neutropenia 71.4%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 90.9%
nausea 66.7%
neutrophil count decreased 51.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.5%
nausea 67.7%
neutrophil count decreased 51.6%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
nausea 75%
asthenia 62.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 61.5%
nausea 61.5%
decreased appetite 42.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.3%
asthenia 60%
headache 53.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
j
neutropenia 57.8% (placebo 2.5%)
nausea 46.8% (placebo 31.1%)
diarrhoea 34% (placebo 22.4%)
NCT02422615 · Phase 3 · combination
show 18 more results
neutropenia 57.9% (placebo 6.5%)
arthralgia 38.8% (placebo 36.2%)
neutrophil count decreased 35.5% (placebo 1.5%)
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
nausea 75% (placebo 32.1%)
anaemia 50% (placebo 7.3%)
diarrhoea 50% (placebo 26.7%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 65.3% (placebo 5.5%)
nausea 54.8% (placebo 32.1%)
fatigue 43.4% (placebo 36.1%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 50.8%
nausea 40.8%
fatigue 38.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 48.1%
nausea 42.1%
fatigue 40.4%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
fatigue 57.7%
neutropenia 57.7%
hot flush 42.3%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 46.5%
nausea 43.3%
fatigue 37.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 100% (placebo 23.4%)
white blood cell count decreased 100% (placebo 33.8%)
anaemia 94.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
aspartate aminotransferase increased 12.5% (placebo 40.3%)
blood alkaline phosphatase increased 6.3% (placebo 27.3%)
blood cholesterol increased 6.3% (placebo 16.9%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 85.7% (placebo 23.4%)
white blood cell count decreased 80.5% (placebo 33.8%)
anaemia 48.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
blood bilirubin increased 1.4% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 88.6% (placebo 23.4%)
white blood cell count decreased 87.3% (placebo 33.8%)
anaemia 55.7% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 2.7% (placebo 23.4%)
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
NCT03671330 · Phase 2 · registry result, not featured evidence
600mg
neutropenia 66.5%
leukopenia 27.7%
anaemia 26.1%
NCT03822468 · Phase 2 · registry result, not featured evidence
400mg
neutropenia 53.2%
alanine aminotransferase increased 26.1%
aspartate aminotransferase increased 21.8%
NCT03822468 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutropenia 65.2%
anaemia 35.7%
leukopenia 25.9%
NCT03839823 · Phase 2 · registry result, not featured evidence
neutropenia 71.7% (placebo 15.3%)
fatigue 33.3% (placebo 32.2%)
aspartate aminotransferase increased 25% (placebo 28.8%)
NCT02632045 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation context differs: eligible sex differs (FEMALE versus ALL).
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation comparability has not been reviewed for both studies.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gTrial phases differ: Phase 1 versus Phase 2.
  8. hPopulation context differs: registered conditions differ.
  9. iPopulation comparability has not been reviewed for 23 of these studies.
  10. jPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Abemaciclib

Disease Control 78.5% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
74.7% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
83% (n=446) vs 75.8% (n=223) placebo
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Disease Control 67.4% (n=132)
responder rate · % of participants
No placebo or comparator arm
NCT02102490 · Phase 2
show 4 more results
40.7% (n=27)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
51.7% (n=58)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
39.3% (n=28)
NCT02308020 · Phase 2 · registry result, not featured evidence
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
Overall Survival Rate at 12 77.2% (n=79) vs 69.8% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 52wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
77.4% (n=79) vs 69.8% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 52wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
OS Rate at 12 55.8% (n=79) vs 43% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 104wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
55.7% (n=79) vs 43% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 104wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
OS 36mo 46.7% (n=79) vs 29.9% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 156wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
40.2% (n=79) vs 29.9% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 156wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
BPI Total Pain 0 vs 0.31 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 vs 0.31 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status -2.9 vs -1.9 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Global health status
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-5.9 vs -1.9 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Global health status
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1 vs -4.5 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Physical functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-4.4 vs -4.5 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Physical functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -2.7 vs -8.2 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Role functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-5 vs -8.2 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Role functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 2.4 vs 1.1 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Emotional functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-0.4 vs 1.1 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Emotional functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Cognitive Functioning -1.8 vs -1.6 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Cognitive functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-1.1 vs -1.6 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Cognitive functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Social Functioning -0.9 vs -2.4 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Social functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-0.9 vs -2.4 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Social functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination

+ 19 further endpoints in the CSV export.

Ribociclib

Time to Response 4.9 vs 3.2 Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 4 more results
NA vs NA placebo months
NCT02422615 · Phase 3 · combination
NA vs NA placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.7 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
3.6 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Time to Progression 27.1 months
time to event · months
No placebo or comparator arm
NCT02941926 · Phase 3 · combination
FACT-B 0.2 score @ 4wk
absolute change · score
No placebo or comparator arm
Cycle 2 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0.1 score @ 8wk
absolute change · score
No placebo or comparator arm
Cycle 3 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.3 score @ 12wk
absolute change · score
No placebo or comparator arm
Cycle 4 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0 score @ 16wk
absolute change · score
No placebo or comparator arm
Cycle 5 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.8 score @ 20wk
absolute change · score
No placebo or comparator arm
Cycle 6 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.9 score @ 28wk
absolute change · score
No placebo or comparator arm
Cycle 8 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -1.2 score @ 36wk
absolute change · score
No placebo or comparator arm
Cycle 10 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -1.6 score @ 44wk
absolute change · score
No placebo or comparator arm
Cycle 12 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -2 score @ 56wk
absolute change · score
No placebo or comparator arm
Cycle 15 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -2 score @ 68wk
absolute change · score
No placebo or comparator arm
Cycle 18 Day 1
NCT02941926 · Phase 3 · combination

+ 38 further endpoints in the CSV export.

Breast Cancer

Shared mechanism: CDK4 and CDK6 · full Breast Cancer pipeline

Abemaciclib · Verzenio

Marketed by Eli Lilly

Approved in Breast Cancersmall molecule
Reliable signal

NCT02107703 · Phase 3 · active, not recruiting

This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.

Next expected readout: December 2026 · NCT05305924 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)

Result source: NCT02107703

Ribociclib

Marketed by Novartis

Approved in Breast Cancersmall molecule
Reliable signal

NCT02422615 · Phase 3 · completed

The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.

Next expected readout: November 2026 · NCT02608216 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)

Result source: NCT02422615

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Abemaciclib: 16 of 16 rows · Ribociclib: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAbemaciclib
Rows use multiple source trials
Ribociclib
Rows use multiple source trials
Clinical Benefit
responder rate · % of participants
72.2% (n=446) vs 56.1% (n=223) placeboa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
42.1% (n=38) vs 15% (n=20) Fulvestrant
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
70.2% (n=484) vs 62.8% (n=242) placeboa,b
NCT02422615 · Phase 3 · combination
3 other source trials
79.1% (n=335) vs 69.7% (n=337) placebo
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
79.6% (n=334) vs 72.8% (n=334) placebo
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
81.3% (n=112) vs 74.5% (n=110) Combination Chemotherapy600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
Clinical Benefit
responder rate · % of participants
No placebo or comparator arm
42.4% (n=132)c,a,d,b
NCT02102490 · Phase 2
4 other source trials
13% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.9% (n=52)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
9.1% (n=22)
NCT02308020 · Phase 2 · registry result, not featured evidence
70.7% (n=3246)c,a,d,b
NCT02941926 · Phase 3 · combination
Duration of Response
time to event · months
NA vs 25.6 placebo monthsa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.36 vs 13.03 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
NA vs NA placebo monthsa,b
NCT02422615 · Phase 3 · combination
3 other source trials
21.3 vs 17.5 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
45.2 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
37 vs 17.6 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Duration of Response
time to event · months
No placebo or comparator arm
8.6 monthse,d,b
NCT02102490 · Phase 2
4 other source trials
11.12 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
17.54 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
5.78 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
4.63 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
28.8 months600 mgf,e,d,b
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
26.5 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
ORR
responder rate · % of participants
35.2% (n=446) vs 16.1% (n=223) placeboa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
26.3% (n=38) vs 10% (n=20) Fulvestrant
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
32.4% (n=484) vs 21.5% (n=242) placeboa,b
NCT02422615 · Phase 3 · combination
3 other source trials
40.9% (n=335) vs 29.7% (n=337) placebo
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
40.7% (n=334) vs 27.5% (n=334) placebo
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
66.1% (n=112) vs 61.8% (n=110) Combination Chemotherapy600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
ORR
responder rate · % of participants
No placebo or comparator arm
19.7% (n=132)c,a,d,b
NCT02102490 · Phase 2
2 other source trials
53.6% (n=224)
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
46.4% (n=224)
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
29.3% (n=3246)c,a,d,b
NCT02941926 · Phase 3 · combination
3 other source trials
41.5% (n=188)400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
45.3% (n=188)600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
16.7% (n=12)
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
ORR
event count · % of participants
No placebo or comparator arm
60.6% (n=33)*1000 mgf,g,h,b
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted
show 3 more doses
19.4% (n=31)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
3.8% (n=26)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
6.7% (n=15)*1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
50% (n=2)*g,h,b
NCT03477396 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
Overall Survival
time to event · months
45.8 vs 37.25 placebo monthsa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
1 other source trial
26.71 vs 26.02 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
NA vs 40 placebo monthsa,b
NCT02422615 · Phase 3 · combination
5 other source trials
NA vs 40.9 placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
63.9 vs 51.4 placebo months
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
NA vs 55.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
69.2 vs 55.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
NA vs NA Combination Chemotherapy months600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
Overall Survival
time to event · months
No placebo or comparator arm
22.32 monthsc,e,d,b
NCT02102490 · Phase 2
4 other source trials
10.06 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
13.38 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
7.13 months
NCT02308020 · Phase 2 · registry result, not featured evidence
2.93 months
NCT02308020 · Phase 2 · registry result, not featured evidence
NA monthsf,c,e,d,b
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
16.4 vs 9.3 placebo monthsa,b
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3 other source trials
5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.28 vs 1.95 Fulvestrant months
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
20.5 vs 12.8 placebo monthsf,a,b
NCT02422615 · Phase 3 · combination
show 1 more dose
NA vs 10.9 placebo months
NCT02422615 · Phase 3 · combination
PFS
time to event · months
No placebo or comparator arm
6 monthsc,e,d,b
NCT02102490 · Phase 2
8 other source trials
2.07 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
4.41 months
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
1.45 months
NCT02308020 · Phase 2 · registry result, not featured evidence
1.22 months
NCT02308020 · Phase 2 · registry result, not featured evidence
13.6 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
2.1 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
NA months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
21.8 monthsf,c,e,d,b
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
show 2 more doses
16.5 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
8.8 months
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
Time to Response
time to event · months
No placebo or comparator arm
3.52 months1000 mgf,g,h,d,b
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
show 3 more doses
5.45 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1.94 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
9.36 months1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
9 months600 mgf,g,h,d,b
NCT03822468 · Phase 2 · registry result, not featured evidence
show 1 more dose
13.1 months400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
Dropout rate
25.6%i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 28 more results
5.3%
NCT02102490 · Phase 2
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
16.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
8.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
25%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
34.5%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
6.6%Abemaciclib
NCT02441946 · Phase 2 · registry result, not featured evidence
2.7%Abemaciclib + Anastrozole
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib + Anastrozole Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib + Anastrozole Cycle 2
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence
17.5%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestoneRibociclib + Fulvestrantj
NCT02422615 · Phase 3 · combination
show 34 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
59.9%
NCT02941926 · Phase 3 · combination
n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestoneRibociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
68.7%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
76.9%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
87.9%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePostmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePremenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
68.8%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
3.2%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
50%
NCT03078751 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—500 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
7.7%Cohort B: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort C: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 28 more results
—
NCT02102490 · Phase 2
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
—Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
—Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
1.3%Abemaciclib
NCT02441946 · Phase 2 · registry result, not featured evidence
1.4%Abemaciclib + Anastrozole
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib + Anastrozole Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib + Anastrozole Cycle 2
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence
—
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
14.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
18.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
12.9%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
25%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
19.2%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
20%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
10.5%Ribociclib + Fulvestrantj
NCT02422615 · Phase 3 · combination
show 34 more results
—Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
15.5%
NCT02941926 · Phase 3 · combination
4.8%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
11.4%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
22.6%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
23.1%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
17.8%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
11.8%PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
—PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
6.5%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
1.3%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
12.8%600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
11.2%400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
7.1%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
—
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
15.4%
NCT03078751 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—500 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—300 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort B: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort C: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
29.3%i
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 28 more results
25%
NCT02102490 · Phase 2
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
12.5%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
33.3%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
21.7%200 mg
NCT03703466 · Phase 2 · registry result, not featured evidence
22.2%Part A Abemaciclib: HR+, HER2+ Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
27.6%Part B Abemaciclib: HR+, HER2- Bre
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
33.3%Part C Abemaciclib: Surgical Resec
NCT02308020 · Phase 2 · registry result, not featured evidence
28.6%Part D Abemaciclib: NSCLC
NCT02308020 · Phase 2 · registry result, not featured evidence
17.4%Part E Abemaciclib: Melanoma
NCT02308020 · Phase 2 · registry result, not featured evidence
41.2%Part F: Abemaciclib HR+ Breast Can
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
—Abemaciclib
NCT02441946 · Phase 2 · registry result, not featured evidence
—Abemaciclib + Anastrozole
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
1.4%Abemaciclib + Anastrozole Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
7.4%Abemaciclib + Anastrozole Cycle 2
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
1.3%Abemaciclib Cycle 1
NCT02441946 · Phase 2 · registry result, not featured evidence
35.9%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
57.1%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
33.3%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
51.6%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
37.5%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
50%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
26.7%1000 mg
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
—Ribociclib + Fulvestrantj
NCT02422615 · Phase 3 · combination
show 34 more results
37.1%Ribociclib + Fulvestrant (On-treat
NCT02422615 · Phase 3 · combination
—
NCT02941926 · Phase 3 · combination
—Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
24.2%Ribociclib + NSAI/Tamoxifen + Gose
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
25%Crossover to Ribociclib + Letrozol
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
32.3%Ribociclib + Letrozole
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30.4%Ribociclib + Letrozole Cohort A
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
27.3%Ribociclib + Letrozole Cohort B
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
19.2%Ribociclib + Letrozole Cohort B1
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
28.7%Ribociclib + Letrozole Cohort B2
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
—PK Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
29.4%PK Cohort - Ribociclib (On-treatme
NCT03671330 · Phase 2 · registry result, not featured evidence
0%PK Cohort - Ribociclib (Post-treat
NCT03671330 · Phase 2 · registry result, not featured evidence
—Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
27.3%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Postmenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
17.7%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
0%Premenopausal Cohort - Ribociclib
NCT03671330 · Phase 2 · registry result, not featured evidence
—600 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
19.7%600mg
NCT03822468 · Phase 2 · registry result, not featured evidence
—400 mg
NCT03822468 · Phase 2 · registry result, not featured evidence
20.2%400mg
NCT03822468 · Phase 2 · registry result, not featured evidence
0%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
—600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
15.2%600 mg
NCT03839823 · Phase 2 · registry result, not featured evidence
6.7%
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
15.4%
NCT03078751 · Phase 2 · registry result, not featured evidence · combination
100%600 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
100%500 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
100%400 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
100%300 mg
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
83.3%Cohort B: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
—Cohort C: Ribociclib + Trastuzumab
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
i
diarrhoea 87.1% (placebo 27.8%)
neutropenia 49.7% (placebo 3.6%)
nausea 49.4% (placebo 24.7%)
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 26 more results
diarrhoea 90.9%
nausea 67.4%
fatigue 47.7%
NCT02102490 · Phase 2
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
200 mg
diarrhoea 87.5%
nausea 62.5%
anaemia 58.3%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 91.7%
nausea 58.3%
anaemia 41.7%
NCT03703466 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 95.7%
anaemia 47.8%
nausea 47.8%
NCT03703466 · Phase 2 · registry result, not featured evidence
diarrhoea 55.6%
fatigue 33.3%
nausea 33.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 77.6%
fatigue 48.3%
nausea 44.8%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
alanine aminotransferase increased 66.7%
anaemia 44.4%
diarrhoea 44.4%
NCT02308020 · Phase 2 · registry result, not featured evidence
diarrhoea 53.6%
fatigue 39.3%
nausea 28.6%
NCT02308020 · Phase 2 · registry result, not featured evidence
abdominal pain 21.7%
diarrhoea 21.7%
neutropenia 21.7%
NCT02308020 · Phase 2 · registry result, not featured evidence
fatigue 52.9%
nausea 41.2%
diarrhoea 35.3%
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 41.9%
constipation 36.5%
fatigue 25.7%
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 46.5%
nausea 30.9%
fatigue 28.6%
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 38.7%
constipation 34.7%
fatigue 22.7%
NCT02441946 · Phase 2 · registry result, not featured evidence
diarrhoea 84.6%
fatigue 43.6%
nausea 43.6%
NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
decreased appetite 66.7%
vomiting 66.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
anaemia 100%
diarrhoea 100%
aspartate aminotransferase increased 85.7%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 85.7%
asthenia 71.4%
neutropenia 71.4%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 90.9%
nausea 66.7%
neutrophil count decreased 51.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.5%
nausea 67.7%
neutrophil count decreased 51.6%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 100%
nausea 75%
asthenia 62.5%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 61.5%
nausea 61.5%
decreased appetite 42.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
1000 mg
diarrhoea 93.3%
asthenia 60%
headache 53.3%
NCT03099174 · Phase 1 · registry result, not featured evidence · combination
j
neutropenia 57.8% (placebo 2.5%)
nausea 46.8% (placebo 31.1%)
diarrhoea 34% (placebo 22.4%)
NCT02422615 · Phase 3 · combination
show 24 more results
neutropenia 57.9% (placebo 6.5%)
arthralgia 38.8% (placebo 36.2%)
neutrophil count decreased 35.5% (placebo 1.5%)
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
nausea 75% (placebo 32.1%)
anaemia 50% (placebo 7.3%)
diarrhoea 50% (placebo 26.7%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 65.3% (placebo 5.5%)
nausea 54.8% (placebo 32.1%)
fatigue 43.4% (placebo 36.1%)
NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 50.8%
nausea 40.8%
fatigue 38.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 48.1%
nausea 42.1%
fatigue 40.4%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
fatigue 57.7%
neutropenia 57.7%
hot flush 42.3%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutropenia 46.5%
nausea 43.3%
fatigue 37.6%
NCT03096847 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 100% (placebo 23.4%)
white blood cell count decreased 100% (placebo 33.8%)
anaemia 94.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
aspartate aminotransferase increased 12.5% (placebo 40.3%)
blood alkaline phosphatase increased 6.3% (placebo 27.3%)
blood cholesterol increased 6.3% (placebo 16.9%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 85.7% (placebo 23.4%)
white blood cell count decreased 80.5% (placebo 33.8%)
anaemia 48.1% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
blood bilirubin increased 1.4% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 88.6% (placebo 23.4%)
white blood cell count decreased 87.3% (placebo 33.8%)
anaemia 55.7% (placebo 13%)
NCT03671330 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 2.7% (placebo 23.4%)
alanine aminotransferase increased 1.4% (placebo 40.3%)
aspartate aminotransferase increased 1.4% (placebo 40.3%)
NCT03671330 · Phase 2 · registry result, not featured evidence
600mg
neutropenia 66.5%
leukopenia 27.7%
anaemia 26.1%
NCT03822468 · Phase 2 · registry result, not featured evidence
400mg
neutropenia 53.2%
alanine aminotransferase increased 26.1%
aspartate aminotransferase increased 21.8%
NCT03822468 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03477396 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutropenia 65.2%
anaemia 35.7%
leukopenia 25.9%
NCT03839823 · Phase 2 · registry result, not featured evidence
neutropenia 71.7% (placebo 15.3%)
fatigue 33.3% (placebo 32.2%)
aspartate aminotransferase increased 25% (placebo 28.8%)
NCT02632045 · Phase 2 · registry result, not featured evidence · combination
neutropenia 53.8% (placebo 0%)
fatigue 46.2% (placebo 4.2%)
nausea 46.2% (placebo 25%)
NCT03078751 · Phase 2 · registry result, not featured evidence · combination
600 mg
neutrophil count decreased 100%
platelet count decreased 100%
anemia 66.7%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
500 mg
neutrophil count decreased 100%
platelet count decreased 100%
anemia 66.7%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
400 mg
anemia 100%
platelet count decreased 100%
white blood cell decreased 100%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
300 mg
anemia 100%
platelet count decreased 100%
white blood cell decreased 100%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination
anemia 83.3%
diarrhea 41.7%
nausea 41.7%
NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation context differs: eligible sex differs (FEMALE versus ALL).
  2. bThe assessment timepoint is not available for both results.
  3. cTrial phases differ: Phase 2 versus Phase 3.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for both studies.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gTrial phases differ: Phase 1 versus Phase 2.
  8. hPopulation context differs: registered conditions differ.
  9. iPopulation comparability has not been reviewed for 28 of these studies.
  10. jPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Abemaciclib

Disease Control 78.5% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
74.7% (n=79) vs 67.1% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
83% (n=446) vs 75.8% (n=223) placebo
NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Disease Control 67.4% (n=132)
responder rate · % of participants
No placebo or comparator arm
NCT02102490 · Phase 2
show 4 more results
40.7% (n=27)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
51.7% (n=58)
NCT02308020 · Phase 2 · registry result, not featured evidence · combination
39.3% (n=28)
NCT02308020 · Phase 2 · registry result, not featured evidence
26.1% (n=23)
NCT02308020 · Phase 2 · registry result, not featured evidence
Overall Survival Rate at 12 77.2% (n=79) vs 69.8% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 52wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
77.4% (n=79) vs 69.8% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 52wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
OS Rate at 12 55.8% (n=79) vs 43% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 104wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
55.7% (n=79) vs 43% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 104wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
OS 36mo 46.7% (n=79) vs 29.9% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 156wk150 mg + 8 mg/kg + 500 mg
responder rate · % of participants
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
40.2% (n=79) vs 29.9% (n=79) Trastuzumab + Standard of Care Chemotherapy @ 156wk150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
BPI Total Pain 0 vs 0.31 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 vs 0.31 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status -2.9 vs -1.9 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Global health status
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
-5.9 vs -1.9 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Global health status
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
-9.5 vs -2.3 Anastrozole score @ 2wk
Global Health Status
NCT02441946 · Phase 2 · registry result, not featured evidence · combination
-7.6 vs -2.3 Anastrozole score @ 2wk
Global Health Status
NCT02441946 · Phase 2 · registry result, not featured evidence
EORTC QLQ-C30 Physical Functioning -1 vs -4.5 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Physical functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-4.4 vs -4.5 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Physical functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Role Functioning -2.7 vs -8.2 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Role functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-5 vs -8.2 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Role functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Emotional Functioning 2.4 vs 1.1 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Emotional functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-0.4 vs 1.1 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Emotional functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Cognitive Functioning -1.8 vs -1.6 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Cognitive functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-1.1 vs -1.6 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Cognitive functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 Social Functioning -0.9 vs -2.4 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg + 500 mg
absolute change · score
Functional scale: Social functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
-0.9 vs -2.4 Trastuzumab + Standard of Care Chemotherapy score150 mg + 8 mg/kg
Functional scale: Social functioning
NCT02675231 · Phase 2 · registry result, not featured evidence · combination

+ 34 further endpoints in the CSV export.

Ribociclib

Time to Response 4.9 vs 3.2 Combination Chemotherapy months600 mg
time to event · months
NCT03839823 · Phase 2 · registry result, not featured evidence
show 4 more results
NA vs NA placebo months
NCT02422615 · Phase 3 · combination
NA vs NA placebo months
NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.7 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
3.6 vs 5.5 placebo months
NCT03671330 · Phase 2 · registry result, not featured evidence
Time to Progression 27.1 months
time to event · months
No placebo or comparator arm
NCT02941926 · Phase 3 · combination
FACT-B 0.2 score @ 4wk
absolute change · score
No placebo or comparator arm
Cycle 2 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0.1 score @ 8wk
absolute change · score
No placebo or comparator arm
Cycle 3 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.3 score @ 12wk
absolute change · score
No placebo or comparator arm
Cycle 4 Day 1
NCT02941926 · Phase 3 · combination
FACT-B 0 score @ 16wk
absolute change · score
No placebo or comparator arm
Cycle 5 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.8 score @ 20wk
absolute change · score
No placebo or comparator arm
Cycle 6 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -0.9 score @ 28wk
absolute change · score
No placebo or comparator arm
Cycle 8 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -1.2 score @ 36wk
absolute change · score
No placebo or comparator arm
Cycle 10 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -1.6 score @ 44wk
absolute change · score
No placebo or comparator arm
Cycle 12 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -2 score @ 56wk
absolute change · score
No placebo or comparator arm
Cycle 15 Day 1
NCT02941926 · Phase 3 · combination
FACT-B -2 score @ 68wk
absolute change · score
No placebo or comparator arm
Cycle 18 Day 1
NCT02941926 · Phase 3 · combination

+ 41 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abemaciclib's landscape · Ribociclib's landscape